相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
Chloe O. C. Orkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
Susan Swindells et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Monthly Injectable Antiretroviral Therapy - Version 1.0 of a New Treatment Approach
Judith S. Currier
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tough requirements for new antiretroviral drugs Comment
Carmen de Mendoza et al.
LANCET HIV (2020)
Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV
Robert C. Bollinger et al.
LANCET HIV (2020)
Ending the HIV Epidemic A Plan for the United States
Anthony S. Fauci et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture
Howard E. Gendelman et al.
TRENDS IN MICROBIOLOGY (2019)
Synthesis of a long acting nanoformulated emtricitabine ProTide
Dhruvkumar Soni et al.
BIOMATERIALS (2019)
Creation of a long-acting rilpivirine prodrug nanoformulation
James R. Hilaire et al.
JOURNAL OF CONTROLLED RELEASE (2019)
A long acting nanoformulated lamivudine ProTide
Nathan Smith et al.
BIOMATERIALS (2019)
Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling
Rajith K. R. Rajoli et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
In Vitro Antiviral Activity of Cabotegravir against HIV-2
Robert A. Smith et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention
Stephanie E. Barrett et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles
Tian Zhou et al.
BIOMATERIALS (2018)
Pharmaceutical nanocrystals: production by wet milling and applications
Maria Malamatari et al.
DRUG DISCOVERY TODAY (2018)
Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1
Tristan D. McPherson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals
Tian Zhou et al.
NANOMEDICINE (2018)
The expanding role of prodrugs in contemporary drug design and development
Jarkko Rautio et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir plus rilpivirine (LATTE-2) in the United States and Spain
Deanna Kerrigan et al.
PLOS ONE (2018)
Creation of a long-acting nanoformulated dolutegravir
Brady Sillman et al.
NATURE COMMUNICATIONS (2018)
Antiretroviral implants for treatment and prevention of HIV infection
Charles Flexner
CURRENT OPINION IN HIV AND AIDS (2018)
Cabotegravir: its potential for antiretroviral therapy and preexposure prophylaxis
Hans-Juergen Stellbrink et al.
CURRENT OPINION IN HIV AND AIDS (2018)
Treatment and prevention of HIV infection with long-acting antiretrovirals
Laura Benitez-Gutierrez et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)
Human carboxylesterases: a comprehensive review
Dandan Wang et al.
ACTA PHARMACEUTICA SINICA B (2018)
Ultra-long-acting removable drug delivery system for HIV treatment and prevention
Martina Kovarova et al.
NATURE COMMUNICATIONS (2018)
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
Raphael J. Landovitz et al.
PLOS MEDICINE (2018)
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial
Miranda I. Murray et al.
HIV CLINICAL TRIALS (2018)
Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques
JoEllyn McMillan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Long-acting slow effective release antiretroviral therapy
Benson Edagwa et al.
EXPERT OPINION ON DRUG DELIVERY (2017)
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
David A. Margolis et al.
LANCET (2017)
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
Martin Markowitz et al.
LANCET HIV (2017)
Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
S. L. Ford et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA)
Kerri J. Penrose et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis
Zara Shubber et al.
PLOS MEDICINE (2016)
Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis
Manjula Gunawardana et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Formulation and pharmacology of long-acting cabotegravir
Christine Trezza et al.
CURRENT OPINION IN HIV AND AIDS (2015)
Intramuscular Administration of Paliperidone Palmitate Extended-Release Injectable Microsuspension Induces a Subclinical Inflammatory Reaction Modulating the Pharmacokinetics in Rats
Nicolas Darville et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Species difference of esterase expression and hydrolase activity in plasma
Fatma Goksin Bahar et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Macrophage endocytic trafficking of antiretroviral nanoparticles
Irena Kadiu et al.
NANOMEDICINE (2011)
Prodrugs-from Serendipity to Rational Design
Kristiina M. Huttunen et al.
PHARMACOLOGICAL REVIEWS (2011)
Prodrugs: design and clinical applications
Jarkko Rautio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Control of product quality in batch crystallization of pharmaceuticals and fine chemicals. Part 1: Design of the crystallization process and the effect of solvent
S Rohani et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2005)
Drug therapy - Adherence to medication
L Osterberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
